2022
Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period
Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia 2022, 36: 2136-2139. PMID: 35761025, PMCID: PMC9243711, DOI: 10.1038/s41375-022-01633-x.Peer-Reviewed Original Research
2017
The multi-faceted potential of CD38 antibody targeting in multiple myeloma
Shallis RM, Terry CM, Lim SH. The multi-faceted potential of CD38 antibody targeting in multiple myeloma. Cancer Immunology, Immunotherapy 2017, 66: 697-703. PMID: 28341874, PMCID: PMC11029060, DOI: 10.1007/s00262-017-1990-2.Peer-Reviewed Original ResearchConceptsCD38 MoAbsEffector mechanismsAutologous stem cell transplantClonal T-cell expansionImmune checkpoint inhibitorsHigh-dose chemotherapyCD38 monoclonal antibodyStem cell transplantMM cell growthT cell expansionAdaptive immune responsesPromising immunotherapeutic agentPivotal clinical studiesPotential tumor antigensMultiple myeloma cellsMM cytotoxicityCheckpoint inhibitorsMM therapyDose chemotherapyMM patientsAntibody therapyCell transplantImmunotherapeutic agentsCD38 antibodyMultiple myeloma